Somatostatin and somatostatin receptors in Cushing's disease

Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents

“…The GPCRs superfamily of receptors, which includes the sst1-5 family, is associated with a number of important physio-pathological functions [41][42][43]. This explains the increasing interest in this research area, which is also supported by the fact that roughly 30% of marketed drugs target GPCRs, as is the case for synthetic SST analogs used to control cell growth and hormonal hypersecretion in pituitary adenomas and other neuroendocrine tumors [44,45].…”

Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists

“…Moreover, sst 2 overexpression prevented octreotide desensitization in these cells (34). Thus, it may be an interesting concept to treat CD patients with cortisol-lowering therapy, which, in case of reappearing sst 2 protein expression, is followed by treatment with an sst 2 -preferring somatostatin analog (35,36). In support of this hypothesis, the primary culture in which octreotide showed the largest ACTH-lowering effect was the one in which sst 2 protein expression was highest, with an immunoreactivity score of 6.…”

Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells

“…Various somatostatin receptor agonists have demonstrated inhibitory effects on tumor cell proliferation in pituitary tumors, including somatotroph and thyrotroph tumors. In some patients with Cushing's disease, SOM230 has shown promising effects by decreasing the levels of plasma ACTH and urinary free cortisol [6,7]. Novel somatostatin-dopamine chimeric molecules or retinoic acid also appear to be a promising approach [8,9].…”